Approfondimenti generali
Neoplasie del polmone, Linee Guida AIOM, 2021. [Apri]
ESMO Clinical Practice Guidelines: Lung and Chest Tumours[Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Gogishvili M, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28:2374-2380.[Apri]
Garassino MC, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023 10;41:1992-1998.[Apri]
Novello S, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 2023;41:1999-2006. [Apri]
Carbone DP, et al. First-line nivolumab + ipilimumab + chemotherapy vs chemotherapy alone in patients with metastatic NSCLC from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype. ASCO 2023 Abstract LBA9023[Apri]